Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
CONCLUSIONS: Patients with T2DM were more likely to achieve clinically important reductions in HbA1c, BW, and systolic BP with canagliflozin versus placebo.
PMID: 29022746 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Hypertension | Invokana | Obesity | Research | SGLT2 Inhibitors | Study | Weight Loss